Understanding Your Pathology Report: Benign Breast Conditions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Medical Directors Arup Medical Directors and Consulting Faculty | 2015
MEDICAL DIRECTORS ARUP MEDICAL DIRECTORS AND CONSULTING FACULTY | 2015 MAY 2015 www.aruplab.com Information in this brochure is current as of May 2015. All content is subject to change. Please contact ARUP Client Services at (800) 522-2787 with any questions or concerns. ARUP LABORATORIES ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. Located in Salt Lake City, Utah, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients’ existing test menus by offering complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP’s clients include many of the nation’s university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®. Since its formation in 1984 by the Department of Pathology at the University of Utah, ARUP has founded its reputation on reliable and consistent laboratory testing and service. This simple strategy contributes significantly to client satisfaction. When ARUP conducts surveys, clients regularly rate ARUP highly and respond that they would recommend ARUP to others. As the most responsive source of quality information and knowledge, ARUP strives to be the reference laboratory of choice for community healthcare systems. -
A Study on Tumor Suppressor Genes Mutations Associated with Different Pppathologicalpathological Cccolorectalcolorectal Lllesions.Lesions
A Study on Tumor Suppressor Genes Mutations Associated with Different PPPathologicalPathological CCColorectalColorectal LLLesions.Lesions. Thesis Submitted for partial fulfillment of the requirements for the Ph.D. degree of Science in Biochemistry By Salwa Naeim Abd ElEl----KaderKader Mater M.Sc. in Biochemistry, 2002 Biological Applications Department Nuclear Research Center Atomic Energy Authority Under the supervision of Prof. Dr. Amani F.H Nour El ---Deen Prof. Dr. Abdel Hady Ali Abdel Wahab Professor of Biochemistry Professor of Biochemistry Biochemistry Department and Molecular Biology Faculty of Science Cancer Biology Department Ain Shams University National Cancer Institute Cairo University Prof. DrDr.MohsenMohsen Ismail Mohamed Dr. Azza Salah Helmy Professor of Clinical Pathology Biological Assistant Professor of Biochemistry Applications Department Biochemistry Department Nuclear Research Center Faculty of Science Atomic Energy Authority Ain Shams University 2012011111 ﺑﺴﻢ ﺍﷲ ﺍﻟﺮﺣﻤﻦ ﺍﻟﺮﺣﻴﻢ ﺇِﻧﻤﺎ ﺃﹶﻣﺮﻩ ﺇِﺫﹶﺍ ﺃﹶﺭﺍﺩ ﺷﻴﺌﹰﺎ ﺃﹶﹾﻥ ﻳﹸﻘﻮﻝﹶ ﻟﹶﻪ ﻛﹸـﻦ ﻓﹶﻴﻜﹸـﻮ ﻥ ﹸ ””” ٨٢٨٨٢٢٨٢““““ﻓﹶﺴﺒﺤﺎﻥﹶ ﺍﱠﻟﺬِﻱ ﺑِﻴﺪِﻩِ ﻣﻠﹶﻜﹸﻮﺕ ﻛﹸـﻞﱢ ﺷـﻲﺀٍ ﻭﺇِﻟﹶﻴـﻪِ ﺗﺮﺟﻌﻮﻥﹶ ””” ٨٣٨٨٣٣٨٣““““ ﺻﺪﻕ ﺍﷲ ﺍﻟﻌﻈﻴﻢ رة (٨٢-٨٣) I declare that this thesis has been composed by myself and the work there in has not been submitted for a degree at this or any other university. Salwa Naeim Abd El-Kader Matter To my dear husband and family Their love, encouragement and help made my studies possible and to them I owe everything. Thank you Salwa Naeim Abd El-Kader Matter Acknowledgement First of all, thanks to Allah the most merciful for guiding me and giving me the strength to complete this work. It is pleasure to express my deepest thanks and profound respect to Prof. -
Simple Technique to Identify Haemosiderin in Immunoperoxidase Stained Sections
J Clin Pathol: first published as 10.1136/jcp.37.10.1190 on 1 October 1984. Downloaded from 1190 Technical methods Phosphate buffer at pH 8*0 gave the sharpest 2 Rozenszajn L, Leibovich M, Shoham D, Epstein J. The esterase staining reactions, although there was little differ- activity in megaloblasts, leukaemic and normal haemopoietic cells. Br J Haematol 1968; 14:605-19. ence at pH 7-0 or pH 7-5. As the buffer pH was 3Hayhoe FGJ, Quaglino D. Haematological cytochemistry. Edin- increased above pH 8-0 staining with both substrates burgh: Churchill Livingstone, 1980. became progressively weaker, especially above pH 4Li CY, Lam KW, Yam LT. Esterases in human leucocytes. J 9.0. Below pH 7-0 staining with a-naphthyl butyrate Histochem Cytochem 1973;21:1-12. Yam LT, Li CY, Crosby WH. Cytochemical identification of became weaker, and below pH 5*0 staining with monocytes and granulocytes. Am J Clin Pathol 1971;55:283- naphthol AS-D chloroacetate began to disappear. 90. 6 Armitage RJ, Linch DC, Worman CP, Cawley JC. The morphol- This work was supported by a Medical Research ogy and cytochemistry of human T-cell subpopulations defined by monoclonal antibodies and Fc receptors. Br J Haematol Council project grant. I thank Professor FGJ 1983;51:605-13. Hayhoe for valuable advice. References Requests for reprints to: Dr DM Swirsky, Department of Gomori G. Chloroacyl esters as histochemical substrates. J His- Haematological Medicine, University Clinical School, Hills tochem Cytochem 1953;1:469-70. Road, Cambridge CB2 2QL, England. Simple technique to identify identification of the two compounds on the same haemosiderin in slide. -
Case Presentation
Open Access Case Report DOI: 10.7759/cureus.2892 Nasal Chondromesenchymal Hamartoma with Skull Base and Orbital Involvement: Case Presentation Denis A. Golbin 1 , Anastasia P. Ektova 2 , Maxim O. Demin 3 , Nikolay Lasunin 4 , Vasily A. Cherekaev 1 1. Skull Base and Craniofacial Surgery, N.N. Burdenko National Medical Research Center for Neurosurgery, Moscow, RUS 2. Pathology, Russian Children's Clinical Hospital, Moscow, RUS 3. Pediatric Neurosurgery, N.N. Burdenko, Moscow, RUS 4. Neuro-Oncology, N.N. Burdenko National Medical Research Center for Neurosurgery, Moscow, RUS Corresponding author: Denis A. Golbin, [email protected] Abstract Nasal chondromesenchymal hamartoma (NCMH) is a rare benign tumor of the sinonasal tract in children with possible orbit and skull base involvement. We present the 57th published observation of this kind of tumor. A 25-month-old female patient presented with recurrent mass lesion of the sinonasal tract. According to her history, she had feeding difficulties and nasal obstruction since birth. She underwent partial resection at eight months of age via transfacial approach in the local hospital. Due to progression of tumor remnants, a second surgery was performed using an endoscopic endonasal approach resulting in subtotal resection. At 12 months of follow-up, a good postoperative result was observed with no signs of tumor progression despite incomplete resection. Histological and immunohistochemical examination of the biopsy specimens is presented. Comparison of specimens obtained from each of the two surgeries showed a difference in histological patterns. Endoscopic endonasal approach is the mainstay of surgical management. In case of incomplete resection, careful follow-up MRI studies should be recommended. -
Phyllodes Tumor of the Vulva: Report of Two Cases Vulvanın Fillods Tümörü: İki Olgu Sunumu
Olgu Sunumu/Case Report doi: 10.5146/tjpath.2013.01153 Phyllodes Tumor of the Vulva: Report of Two Cases Vulvanın Fillods Tümörü: İki Olgu Sunumu İrem Hicran Özbudak1, Hampar Akkaya2, Bahar Akkaya1, Gülgün ERDOĞAN1, Hadice Elif PEŞTERElİ1, Fatma Şeyda Karavelİ1 1Department of Pathology, Akdeniz University, Faculty of Medicine, ANTALYA, TURKEY, 2Başkent University, Faculty of Medicine, Alanya Hospital, ANTALYA, TURKEY ABSTRACT ÖZ Ectopic breast tissue can occur anywhere along the primitive Ektopik meme dokusu ilkel embriyonik sütyolu boyunca herhangi bir embryonic milk line and can be the site of the same pathologic yerde ortaya çıkabilir ve normal memede izlenebilen aynı patolojik processes found in the normal breast. Phyllodes tumor is an durumlar ektopik meme dokusunda da görülebilir. Fillods tümör extremely rare fibroepithelial neoplasm that occurs in ectopic breast vulvadaki ektopik meme dokusunda oluşan nadir bir fibroepitelyal tissue of the vulva. To date, only 8 cases of phyllodes tumor in the neoplazidir. Literatürde bugüne kadar 8 olgu bildirilmiştir. Bu vulva have been reported in the literature. This paper presents two makalede literatüre ek olarak iki ayrı vulvar fillods tümör vakası additional case of benign phyllodes tumor in the vulva. The first sunulmuştur. İlk olgu, sol ön mons pubiste boyutu son üç ayda artış patient was a 43-year-old woman, presenting with a lesion on the gösteren bir lezyon ile kliniğe başvurmuş 43 yaşında kadın hastadır. left anterior mons pubis that had increased in size in the last three İkinci olgu 50 yaşında kadın hasta olup, iki aydır varolan sağ labium months. The second patient was a 50-year-old woman, presenting majusta kitle ile başvurmuştur. -
BRAIN TUMORS Info Sheet
ROSWELL PARK COMPREHENSIVE CANCER CENTER BRAIN TUMORS Info Sheet FAST FACTS WHAT YOU SHOULD KNOW When cells in the brain grow and multiply out of control, they can form a tumor which may be malignant (cancerous) or benign (not cancerous). Roswell Park treats both malignant and benign tumors in the brain. Malignant brain tumors contain cancer cells and tend to grow rapidly and invade healthy brain tissue. Many of these are treatable and new therapies can help patients live longer and preserve quality of life. THERE ARE Benign brain tumors do not contain cancer cells. They rarely invade nearby MORE THAN tissue or spread to other parts of the body. Although a benign tumor is not DIFFERENT cancerous, it still needs treatment because it can press on the brain as it 120 TYPES OF grows in the skull. BRAIN TUMORS ARE YOU AT RISK? Brain tumors are relatively rare. They can occur at any age but are most Brain tumors common in children and older adults. You may have an increased risk for occur mostly in developing a brain tumor if you have one of these factors: children younger in adults Prior radiation treatment for other medical conditions such as leukemia. than older than Certain genetic conditions in your family. About 5% of brain tumors are linked to: 15 65 Neurofibromatosis Tuberous sclerosis & Von Hippel-Lindau disease Li-Frameni syndrome SYMPTOMS TO TELL YOUR DOCTOR The chance Persistent daily headaches of developing Changes in speech, vision or hearing a malignant Problems balancing or walking brain Changes in mood, personality or ability to concentrate tumor Confusion or difficulty with memory is LESS Muscle jerking or twitching THAN (seizures or convulsions) Numbness, weakness or 1% tingling in arms or legs 1-800-ROSWELL (1-800-767-9355) | RoswellPark.org If you have a brain tumor, WHY ROSWELL PARK FOR BRAIN TUMORS? you need a second opinion. -
Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA Or KRAS Mutations
pISSN 1598-2998, eISSN 2005-9256 Cancer Res Treat. 2020;52(4):1219-1228 https://doi.org/10.4143/crt.2019.688 Original Article Open Access Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations Aiko Ogasawara, MD1 Purpose Taro Hihara, PhD2 Circulating tumor DNA (ctDNA) is an attractive source for liquid biopsy to understand Daisuke Shintani, MD1 molecular phenotypes of a tumor non-invasively, which is also expected to be both a diag- nostic and prognostic marker. PIK3CA and KRAS are among the most frequently mutated Akira Yabuno, MD1 genes in epithelial ovarian cancer (EOC). In addition, their hotspot mutations have already MD, PhD1 Yuji Ikeda, been identified and are ready for a highly sensitive analysis. Our aim is to clarify the signifi- 2 Kenji Tai, MSc cance of PIK3CA and KRAS mutations in the plasma of EOC patients as tumor-informed 1 Keiichi Fujiwara, MD, PhD ctDNA. Keisuke Watanabe, BSc2 Materials and Methods Kosei Hasegawa, MD, PhD1 We screened 306 patients with ovarian tumors for somatic PIK3CA or KRAS mutations. A total of 85 EOC patients had somatic PIK3CA and/or KRAS mutations, and the correspon- ding mutations were subsequently analyzed using a droplet digital polymerase chain reac- 1Department of Gynecologic Oncology, tion in their plasma. Saitama Medical University International Results Medical Center, Hidaka, 2Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan The detection rates for ctDNA were 27% in EOC patients. Advanced stage and positive peritoneal cytology were associated with higher frequency of ctDNA detection. Preopera- tive ctDNA detection was found to be an indicator of outcomes, and multivariate analy- sis revealed that ctDNA remained an independent risk factor for recurrence (p=0.010). -
Brain Tumors
Understanding Brain Tumors Jana, diagnosed in 1999, with her husband, Paul. SAMPLE COPYRIGHTED What Is a Brain Tumor? A brain tumor, like other tumors, is a collection of cells that multiply at a rapid rate. The tumor may cause damage by pressing on or spreading into healthy parts of the brain and interfering with function. Brain tumors can be benign or malignant. They can develop outside or inside the brain. A benign tumor is noncancerous but not necessarily harmless. Benign tumors tend to grow slowly. Symptoms may not appear for a long time. These tumors are often detected incidentally, or by accident. For example, a benign tumor may be discovered when a brain scan is performed because of a headache or after a car accident. A benign tumor usually has distinct borders and is less likely to cause damage to surrounding tissue. Malignant tumors are cancerous. Malignant tumors tend to grow aggressively and spread to surrounding tissues. Despite treatment, they may recur either in the same place or in another location. A malignant tumor, if left untreated, can ultimately lead to death. Malignant brain tumors are among the most difficult types of cancer to fight. Malignant brain tumors are classified as either primary or secondary. A primary tumor means the cancerous cells start in the brain. In a secondary—or metastatic—tumor, the cancerous cells start elsewhere in the body. They then spread through the bloodstream to the brain. This process is known as metastasis. More than 120 different types of brain tumors have been identified. What Causes Brain Tumors? When diagnosed with a brain tumor, a person might wonder, why me? Unfortunately, the current understanding of the causes and possible risk factors for brain tumors is limited. -
Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline Or High-Risk Lesions
- Official Statement - Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions Purpose To outline the management approach for borderline and high risk lesions identified on image-guided breast biopsy. Associated ASBrS Guidelines or Quality Measures 1. Image-Guided Percutaneous Biopsy of Palpable and Nonpalpable Breast Lesions 2. Performance and Practice Guidelines for Stereotactic Breast Procedures 3. Concordance Assessment Following Image-Guided Breast Biopsy Methods Literature review inclusive of recent randomized controlled trials evaluating the management of various borderline and high-risk lesions (including atypical hyperplasia, lobular neoplasia, papillary lesions, radial scars and complex sclerosing lesions, fibroepithelial lesions, mucocele-like lesions, spindle cell lesions, and pseudoangiomatous stromal hyperplasia [PASH]) identified on image-guided breast biopsies. This is not a complete systematic review but a comprehensive review of the modern literature on this subject. The ASBS Research Committee developed a consensus document which the ASBS Board of Directors reviewed and approved. Summary of Data Reviewed Percutaneous core needle biopsy (CNB) is the preferred, initial, minimally invasive diagnostic procedure for nonpalpable breast lesions or palpable breast masses.1 Concordance assessment of the histologic, imaging, and clinical findings determines further management. Discordance refers to the situation in which a breast CNB demonstrates benign histology, while the clinical or imaging findings are suspicious for malignancy. If there is discordance between imaging and pathology, histological evaluation is still needed. This can be accomplished either by repeat CNB, perhaps with consideration of larger gauge or vacuum- assisted device, or surgical excision.2-5 Some nonmalignant CNB findings are considered “borderline” because of their potential association with malignancy. -
2021 Anatomic & Clinical Pathology
BEAUMONT LABORATORY 2021 ANATOMIC & CLINICAL PATHOLOGY Physician Biographies Expertise BEAUMONT LABORATORY • 800-551-0488 BEAUMONT LABORATORY ANATOMIC & CLINICAL PATHOLOGY • PHYSICIAN BIOGRAPHIES Peter Millward, M.D. Mitual Amin, M.D. Chief of Clinical Pathology, Beaumont Health Interim Chair, Pathology and Laboratory Medicine, Interim Chief of Pathology Service Line, Beaumont Health Royal Oak Interim Physician Executive, Beaumont Medical Group Interim Chair, Department of Pathology and Laboratory Medicine, Oakland University William Beaumont School Interim System Medical Director, Beaumont Laboratory of Medicine Outreach Services Board certification Associate Medical Director, Blood Bank and • Anatomic and Clinical Pathology, Transfusion Medicine, Beaumont Health American Board of Pathology Board certification Additional fellowship training • Anatomic and Clinical Pathology, • Surgical Pathology American Board of Pathology Special interests Subspecialty board certification • Breast Pathology, Genitourinary Pathology, • Blood Banking and Transfusion Medicine, Gastrointestinal Pathology American Board of Pathology Lubna Alattia, M.D. Kurt D. Bernacki, M.D. Cytopathologist and Surgical Pathologist, Trenton System Medical Director, Surgical Pathology Board certification Beaumont Health • Anatomic and Clinical Pathology, Chief, Pathology Laboratory, West Bloomfield American Board of Pathology Breast Care Center Subspecialty board certification Diagnostic Lead, Pulmonary Tumor Pathology • Cytopathology, American Board of Pathology Diagnostic -
Rotana Alsaggaf, MS
Neoplasms and Factors Associated with Their Development in Patients Diagnosed with Myotonic Dystrophy Type I Item Type dissertation Authors Alsaggaf, Rotana Publication Date 2018 Abstract Background. Recent epidemiological studies have provided evidence that myotonic dystrophy type I (DM1) patients are at excess risk of cancer, but inconsistencies in reported cancer sites exist. The risk of benign tumors and contributing factors to tu... Keywords Cancer; Tumors; Cataract; Comorbidity; Diabetes Mellitus; Myotonic Dystrophy; Neoplasms; Thyroid Diseases Download date 07/10/2021 07:06:48 Link to Item http://hdl.handle.net/10713/7926 Rotana Alsaggaf, M.S. Pre-doctoral Fellow - Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH PhD Candidate – Department of Epidemiology & Public Health, University of Maryland, Baltimore Contact Information Business Address 9609 Medical Center Drive, 6E530 Rockville, MD 20850 Business Phone 240-276-6402 Emails [email protected] [email protected] Education University of Maryland – Baltimore, Baltimore, MD Ongoing Ph.D. Epidemiology Expected graduation: May 2018 2015 M.S. Epidemiology & Preventive Medicine Concentration: Human Genetics 2014 GradCert. Research Ethics Colorado State University, Fort Collins, CO 2009 B.S. Biological Science Minor: Biomedical Sciences 2009 Cert. Biomedical Engineering Interdisciplinary studies program Professional Experience Research Experience 2016 – present Pre-doctoral Fellow National Cancer Institute, National Institutes -
Cytopathology Surgical Pathology
CLINICAL INFORMATICS CYTOPATHOLOGY HEMATOPATHOLOGY SURGICAL PATHOLOGY This is a two-year ACGME-accredited fellowship This one-year fully accredited program This is a one-year, fully accredited fellowship This is a one-year program designed to give includes cross-disciplinary learning for physicians provides advanced training in diagnostic in hematology/hematopathology with an the fellow experience working at the junior from different medical specialties. Training cytology. The experience includes daily optional non-accredited second year faculty level. The fellowship is based at the includes specialized coursework in foundational sign-out of gynecologic and dedicated to research in hematopathology. University Hospital, with annual surgical CI as well as healthcare analytics, cybersecurity, nongynecologic specimens as well as The hematopathology fellowship includes pathology volume of 24,000 specimens. and data science. Fellows will work with the training in the performance and comprehensive training in laboratory program director to develop an individualized interpretation of fine needle aspiration hematology and interpretation of tissue Clinical duties include daily review of RUSH learning plan including foundational knowledge biopsies. Participation in conferences and biopsies performed for hematolymphoid and STAT cases, serving as first-line as well as elective opportunities (e.g., healthcare teaching of pathology residents and disorders. The accredited year of fellowship consultant to resident and student trainees, business intelligence, machine learning/artificial cytotechnology students is required. training includes core training in the clinical frozen section interpretation, organization intelligence, population/community health, hematology laboratory at University Hospital of conferences, participation in surgical bioinformatics for large scale-nucleic acid Involvement in clinical research is also and the flow cytometry, molecular pathology quality improvement activities, sequencing and clinical metabolomics, sensor encouraged.